Pembrolizumab provides long‐term survival benefits in advanced non‐small cell lung cancer: The 5‐year outcomes of the KEYNOTE‐024 trial

QR Code

Pembrolizumab provides long‐term survival benefits in advanced non‐small cell lung cancer: The 5‐year outcomes of the KEYNOTE‐024 trial

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Fengtan Li, Xifeng Dong
Format:	article
Langue:	EN
Publié:	Wiley 2021
Sujets:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Accès en ligne:	https://doaj.org/article/a69bfb0defa04ea3b11f96a5ccff03e2
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Pembrolizumab-Induced Adrenal Insufficiency in Patients with Untreated Advanced Non-Small Cell Lung Cancer: A Case Series
par: Kei Sonehara, et autres
Publié: (2021)

Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer
par: Weinberg F, et autres
Publié: (2019)

KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
par: Antoni Ribas, et autres
Publié: (2020)

The Survival Benefit for Optimal Glycemic Control in Advanced Non-Small Cell Lung Cancer Patients With Preexisting Diabetes Mellitus
par: Jie Qian, et autres
Publié: (2021)

Keynote Speakers
par: Challenging Glass
Publié: (2018)

Keynote Speakers
par: Challenging Glass
Publié: (2016)

Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives
par: Somasundaram A, et autres
Publié: (2017)

Pembrolizumab-Induced Lichen Planus on the Scalp of a Patient with Non-Small-Cell Lung Carcinoma
par: Aya Yamashita, et autres
Publié: (2021)

Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer
par: Noguchi S, et autres
Publié: (2020)

Prognostic Value of Baseline Medications Plus Neutrophil-to-Lymphocyte Ratio in the Effectiveness of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer: A Retrospective Study
par: Toshiki Ogiwara, et autres
Publié: (2021)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer.
par: Qiao Liu, et autres
Publié: (2021)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer
par: Qiao Liu, et autres
Publié: (2021)

Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival
par: Hui Zheng, et autres
Publié: (2021)

CT based radiomic approach on first line pembrolizumab in lung cancer
par: Marta Zerunian, et autres
Publié: (2021)

Keynote Address to the International Seminar on Malik Bennabi
par: Anwar Ibrahim
Publié: (1992)

Factors associated with immunotherapy respond and survival in advanced non-small cell lung cancer patients
par: Yahua Wu, et autres
Publié: (2022)

Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study
par: Jie Zhang PhD, et autres
Publié: (2021)

Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer.
par: Christine S Walsh, et autres
Publié: (2021)

ECLAC keynotes for development No 3: Foreign Direct Investment
Publié: (2018)

ECLAC keynotes for development No 1: Foreign Direct Investment
Publié: (2017)

ECLAC keynotes for development No 4: International Trade Outlook
Publié: (2019)

Clinical case of long-term use of durvalumab in the treatment of advanced small-cell lung cancer
par: Galina B. Statsenko, et autres
Publié: (2020)

Phase III trials examining the efficacy of cetirizine ophthalmic solution 0.24% compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challenge model
par: Meier EJ, et autres
Publié: (2018)

Safety of cetirizine ophthalmic solution 0.24% for the treatment of allergic conjunctivitis in adult and pediatric subjects
par: Malhotra RP, et autres
Publié: (2019)

First-line pembrolizumab plus chemotherapy for extensive-stage small-cell lung cancer: a United States-based cost-effectiveness analysis
par: Youwen Zhu, et autres
Publié: (2021)

Dramatic, significant metabolic response to a one‐time pembrolizumab treatment following a relapse of pre‐existing organizing pneumonia in a patient with advanced non‐small cell lung cancer: A case report
par: Motoyasu Kato, et autres
Publié: (2021)

Cooperation among unrelated ant queens provides persistent growth and survival benefits during colony ontogeny
par: Madeleine M. Ostwald, et autres
Publié: (2021)

Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and place in therapy
par: Addis VM, et autres
Publié: (2018)

Pretreatment Glasgow prognostic score and prognostic nutritional index predict overall survival of patients with advanced small cell lung cancer
par: Minami S, et autres
Publié: (2017)

Does Warfarin or Rivaroxaban at Low Anticoagulation Intensity Provide a Survival Benefit to Asian Patients With Atrial Fibrillation?
par: Dong Lin, et autres
Publié: (2021)

Two randomized trials provide no consistent evidence for nonmusical cognitive benefits of brief preschool music enrichment.
par: Samuel A Mehr, et autres
Publié: (2013)

Prognostic significance of the albumin-to-globulin ratio for advanced urothelial carcinoma treated with pembrolizumab: a multicenter retrospective study
par: Satoru Taguchi, et autres
Publié: (2021)

Design of 1 280×1 024 DI Multi-Functional IRFPA Readout Circuit
par: Qiu Tianhui, Xia Xiaojuan, Liu Qi, Guan Yu
Publié: (2021)

Keynote address by the Minister of Finance of Trinidad and Tobago, the Honourable Brian Kue Tung
par: Tung, Brian Kuei
Publié: (2014)

Afatinib treatment in advanced non-small cell lung cancer
par: Hurwitz JL, et autres
Publié: (2011)

Advances in Biomarkers for Immunotherapy of Non-small Cell Lung Cancer
par: Chuan HUANG, et autres
Publié: (2021)

Hypertrophic lichenoid dermatitis during pembrolizumab treatment
par: Ryoma Honda, et autres
Publié: (2021)

Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates
par: Mary L Disis, et autres
Publié: (2021)

Keynote Closing Address for EAC12: The Worldwide State of Experimental Archaeology and the Agenda for the Future
par: Linda Hurcombe, et autres
Publié: (2021)

Educating Well: A Keynote on a Future Paradigm for Applied Arts and Health in Education
par: Ross W. Prior, et autres
Publié: (2021)